APA ציטוט

Hong, J., Kwon, G. Y., Kang, M., Seo, S. I., & Park, S. H. (2024). Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study. Korean Urological Oncology Society.

Chicago Style (17th ed.) Citation

Hong, Joohyun, Ghee Young Kwon, Minyong Kang, Seong Il Seo, and Se Hoon Park. Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study. Korean Urological Oncology Society, 2024.

ציטוט MLA

Hong, Joohyun, et al. Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study. Korean Urological Oncology Society, 2024.